Discover what Emgality® can do for patients with episodic migraine1

For your patients with 4-14 MHDs per month,1

Review safety profile or the results from the 12-month, open-label safety study for Emgality


  1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
  2. Data on File. Lilly USA, LLC. DOF-GZ-US-0002.
  3. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088.
  4. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.
  5. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019.
  6. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019.
  7. Vyepti [Prescribing Information]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.; 2020.
  8. Data on File. Lilly USA, LLC. DOF-GZ-US-0147.
  9. Data on File. Lilly USA, LLC. DOF-GZ-US-0148.
  10. Data on File. Lilly USA, LLC. DOF-GZ-US-0171.
  11. Data on File. Lilly USA, LLC. DOF-GZ-US-0173.
  12. Data on File. Lilly USA, LLC. DOF-GZ-US-0120.
  13. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409-421.


Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.



Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache